Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China · Delayed Price · Currency is CNY 4.140
+0.030 (0.73%)
Apr 29, 2026, 3:04 PM CST
SHE:300194 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,678 | 1,738 | 2,308 | 2,571 | 2,378 | 2,388 |
Other Revenue | - | - | 83.1 | 76.94 | 44.22 | 64.71 |
| 1,678 | 1,738 | 2,391 | 2,648 | 2,422 | 2,453 | |
Revenue Growth (YoY) | -18.13% | -27.31% | -9.68% | 9.33% | -1.28% | 3.58% |
Cost of Revenue | 1,061 | 1,096 | 1,174 | 1,281 | 1,066 | 935.97 |
Gross Profit | 617.4 | 642.58 | 1,218 | 1,367 | 1,355 | 1,517 |
Selling, General & Admin | 399.91 | 414.73 | 804.89 | 1,021 | 1,092 | 1,217 |
Research & Development | 130.42 | 134.66 | 153.22 | 148.79 | 142.89 | 120.38 |
Other Operating Expenses | -3.62 | -3.18 | 6.9 | 15.31 | 16.28 | 28.08 |
Operating Expenses | 526.71 | 546.2 | 968.97 | 1,182 | 1,255 | 1,370 |
Operating Income | 90.69 | 96.38 | 248.55 | 184.51 | 100.24 | 147.59 |
Interest Expense | - | - | -23.34 | -29.57 | -26.94 | -20.45 |
Interest & Investment Income | 128.27 | 138.26 | 106.8 | 109.41 | 90.07 | 74.46 |
Currency Exchange Gain (Loss) | - | - | 0.98 | 0.66 | 1.47 | -0.59 |
Other Non Operating Income (Expenses) | -0.11 | -0.22 | -0.45 | -0.85 | -1.4 | -1.76 |
EBT Excluding Unusual Items | 218.85 | 234.42 | 332.54 | 264.17 | 163.44 | 199.26 |
Impairment of Goodwill | - | - | - | -224.51 | -22.97 | -201.06 |
Gain (Loss) on Sale of Investments | -1.69 | -1.86 | -32.74 | 0.41 | 0.42 | 0.75 |
Gain (Loss) on Sale of Assets | 0.26 | 0.27 | 0.01 | 220.65 | 4.85 | 0.31 |
Asset Writedown | -147.76 | -149.58 | -4.92 | -3.61 | -2.44 | -626.17 |
Other Unusual Items | - | - | 17.3 | 33.24 | 46.07 | 34.93 |
Pretax Income | 69.67 | 83.24 | 312.2 | 290.36 | 189.35 | -591.99 |
Income Tax Expense | 7.2 | 6.76 | 34.03 | 55.95 | -11.47 | 17.61 |
Earnings From Continuing Operations | 62.46 | 76.49 | 278.17 | 234.41 | 200.82 | -609.59 |
Minority Interest in Earnings | 0.4 | 0.51 | 1.67 | -2.54 | 3.79 | 312.68 |
Net Income | 62.86 | 77 | 279.84 | 231.87 | 204.61 | -296.91 |
Net Income to Common | 62.86 | 77 | 279.84 | 231.87 | 204.61 | -296.91 |
Net Income Growth | -72.23% | -72.48% | 20.69% | 13.32% | - | - |
Shares Outstanding (Basic) | 1,283 | 1,283 | 1,166 | 1,220 | 1,204 | 1,188 |
Shares Outstanding (Diluted) | 1,283 | 1,283 | 1,166 | 1,220 | 1,204 | 1,188 |
Shares Change (YoY) | 10.84% | 10.06% | -4.46% | 1.40% | 1.34% | 2.10% |
EPS (Basic) | 0.05 | 0.06 | 0.24 | 0.19 | 0.17 | -0.25 |
EPS (Diluted) | 0.05 | 0.06 | 0.24 | 0.19 | 0.17 | -0.25 |
EPS Growth | -74.95% | -75.00% | 26.32% | 11.77% | - | - |
Free Cash Flow | 280.61 | 203.89 | 61.8 | 113.3 | -43.6 | -155.91 |
Free Cash Flow Per Share | 0.22 | 0.16 | 0.05 | 0.09 | -0.04 | -0.13 |
Dividend Per Share | - | - | 0.050 | 0.050 | 0.050 | - |
Gross Margin | 36.79% | 36.97% | 50.91% | 51.63% | 55.97% | 61.85% |
Operating Margin | 5.41% | 5.54% | 10.39% | 6.97% | 4.14% | 6.02% |
Profit Margin | 3.75% | 4.43% | 11.70% | 8.76% | 8.45% | -12.10% |
Free Cash Flow Margin | 16.72% | 11.73% | 2.58% | 4.28% | -1.80% | -6.35% |
EBITDA | 296.61 | 300.53 | 445.63 | 392.88 | 284.11 | 321.89 |
EBITDA Margin | 17.68% | 17.29% | 18.63% | 14.84% | 11.73% | 13.12% |
D&A For EBITDA | 205.92 | 204.15 | 197.08 | 208.37 | 183.87 | 174.29 |
EBIT | 90.69 | 96.38 | 248.55 | 184.51 | 100.24 | 147.59 |
EBIT Margin | 5.41% | 5.54% | 10.39% | 6.97% | 4.14% | 6.02% |
Effective Tax Rate | 10.34% | 8.12% | 10.90% | 19.27% | - | - |
Revenue as Reported | - | - | 2,391 | 2,648 | 2,422 | 2,453 |
Advertising Expenses | - | - | 24.05 | 2.44 | 0.48 | 0.5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.